Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dicerna Pharmaceutic (DRNA)

Dicerna Pharmaceutic (DRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.

DRNA : 38.22 (+0.58%)
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s...

DRNA : 38.22 (+0.58%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COR, STXB, BCML, DRNA; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: CoreSite Realty Corporation (NYSE:COR) concerning...

COR : 219.50 (-0.20%)
STXB : 25.55 (-0.23%)
BCML : 23.30 (-0.72%)
DRNA : 38.22 (+0.58%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DRNA, RRD, LEVL, HRC; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) concerning...

DRNA : 38.22 (+0.58%)
RRD : 10.84 (unch)
LEVL : 39.93 (-0.94%)
HRC : 155.96 (+0.03%)
Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders....

DRNA : 38.22 (+0.58%)
Novo Nordisk to Acquire Dicerna

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company...

DRNA : 38.22 (+0.58%)
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared...

DRNA : 38.22 (+0.58%)
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled,...

DRNA : 38.22 (+0.58%)
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended...

DRNA : 38.22 (+0.58%)
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial...

DRNA : 38.22 (+0.58%)

Barchart Exclusives

European Commodities: Brent Crude Attempts to Make a Comeback
Here are the key levels to watch for Brent crude futures right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar